Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (38,422,700)	$ (16,423,506)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash consideration for acquired in-process research and development		6,541,485
Change in fair value of contingent consideration liability	22,320,000
Impairment charge		1,000,000
Stock-based compensation expense	1,865,520	985,260
Depreciation	182,650	181,314
Amortization	36,282	135,664
Unrealized gains on foreign currency exchange	(44,323)	(3,310)
Changes in fair value of warrant liability		(30,000)
Changes in operating assets and liabilities:
Accounts receivable	(2,815,343)	2,449,447
Prepaid expenses and other current assets	(636,943)	179,298
Accounts payable	856,653	(322,976)
Accrued expenses and other liabilities	1,199,708	(2,274,497)
Tax refund receivable	(5,564,759)	40,376
Deferred taxes		(58,500)
Net cash used in operating activities	(21,023,255)	(7,599,945)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of short-term investments	39,385,689
Purchases of short-term investments	(74,413,135)	(28,207,073)
Purchase of property and equipment	(100,329)	(1,227)
Cash paid for internally developed patents	(98,893)	(25,396)
Net cash used in investing activities	(35,226,668)	(28,233,696)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash paid in conjunction with warrant exchange		(25,000)
Payments of deferred offering costs	(160,522)
Proceeds from exercises of warrants	41,038,458	30,324
Proceeds from issuance of common stock in at the market offering, net	25,614,836
Proceeds from issuance of common stock and pre-funded warrants in public offering, net	124,027,815
Proceeds from issuance of common stock in registered direct offering, net		12,668,784
Proceeds from issuance of notes payable	632,000
Payments of notes payable	(632,000)	(186,940)
Proceeds from issuance of common stock from Employee Stock Purchase Plan	135,471
Proceeds from exercises of stock options	126,445
Net cash provided by financing activities	190,782,503	12,487,168
Net increase and decrease in cash and cash equivalents and restricted cash	134,532,580	(23,346,473)
Cash, cash equivalents and restricted cash at beginning of period	8,996,860	34,353,129
Cash, cash equivalents and restricted cash at end of period	143,529,440	11,006,656
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$ 1,791
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES:
Common stock issued for acquired in-process research and development		$ 3,791,485